Drospirenone Drug Asset Due Diligence Report 2026

This Drospirenone Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 24 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Drospirenone can convert its Small molecule drug profile and AR x MR x PR x Testosterone congeners biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Drospirenone (query alias: Drospirenone)
Modality / target	Small molecule drug; AR x MR x PR x Testosterone congeners; AR antagonists, MR antagonists, PR agonists
Highest global status	Approved
Originator	Exeltis USA, Inc.
Active developers	Duchesnay, Inc., Hyundai Pharmaceutical Co., Ltd., Insud Pharma SL

The MCP disease footprint includes Contraception, Endometriosis, Dysmenorrhea. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
JPRN-jRCT1031250728	Phase 4	募集前	30	1. Change from baseline in objective findings (FAI)-the endpoint is defined as the change from baseline at Cycle 6 (end of the observation period). 2. Change from baseline in subjective assessments (FSFI score, K6 score)-the endpoint is defined as the change from baseline at Cycle 6 (end of the observation period). 3. Correlation between (1) and (2)
TCTR20260211001	Phase 3	Pending (Not yet recruiting)	66	Not disclosed
NCT07340190	Phase 1	Recruiting	24	Maximum Plasma Concentration (Cmax) of repaglinide, midazolam, and drospirenone and ethinyl estradiol

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Evidence gap

The Clinical Trials MCP returned no matched public result record. This is a gating diligence gap, not evidence of failure.

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Drospirenone addresses Contraception, Endometriosis, Dysmenorrhea. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2022-06-23	ASKA Pharmaceutical and Hyundai Pharm have entered into an agreement	Approved	Financial terms not disclosed
2022-05-17	Duchesnay partners with Exeltis to bring Slynd, a female contraceptive, to the market in Canada.	Approved	Financial terms not disclosed
2020-01-08	ASKA collaborates with Insud to develop and commercialize drospirenone as an API in Japan, with sublicense rights in the Republic of Korea.	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Methods using combined oral contraceptive compositions with reduced cardiovascular effects”. The milestone feed surfaced a patent-application signal described as “Cortexolone-17Αlpha-propionate combinations for treating acne”. The milestone feed surfaced a patent-application signal described as “A composition comprising estetrol and drospirenone for use in treating unscheduled bleeding in adolescents”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO